Literature DB >> 16597839

Agonist-induced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homo-oligomer.

Michael M C Kong1, Theresa Fan, George Varghese, Brian F O'dowd, Susan R George.   

Abstract

The role of oligomerization in D1 dopamine receptor trafficking to the cell surface was examined using conformationally distinct variants of this receptor. Substitution of the highly conserved aspartic acid (Asp103) in transmembrane domain 3 resulted in a constitutively active receptor, D103A, that did not bind agonists or antagonists but trafficked to the cell surface as oligomers. Coexpression of D103A with the wild-type D1 receptor in human embryonic kidney 293t cells resulted in inhibition of cell surface expression of the D1 receptor because of receptor oligomerization, causing intracellular retention of both proteins. Rescue of the intracellularly retained oligomer could be achieved only by membrane-permeable full and partial agonists, which resulted in cell surface expression of the D1 receptor, whereas cell-permeable antagonists and cell impermeable agonists had no effect. Cell surface fluorescence resonance energy transfer studies of cells coexpressing D103A and D1 revealed no signal before agonist treatment but a robust signal after agonist treatment, indicating that the intact D1/D103A oligomer reached the cell surface only after agonist treatment but not under basal conditions. This suggests that rescue of the retained D1/D103A oligomer to the cell surface was a result of an agonist-induced change in the conformation of D1, permitting cell surface trafficking of the D1/D103A receptor oligomeric complex from the endoplasmic reticulum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16597839     DOI: 10.1124/mol.105.021246

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

2.  Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.

Authors:  Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I Canela; Rob Leurs; Sergi Ferré; Carme Lluís; Rafael Franco
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 3.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

4.  Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

Authors:  Juan Pablo Cueva; Alejandra Gallardo-Godoy; Jose I Juncosa; Pierre A Vidi; Markus A Lill; Val J Watts; David E Nichols
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

5.  Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.

Authors:  Mark Slifstein; Raymond F Suckow; Jonathan A Javitch; Thomas Cooper; Jeffrey Lieberman; Anissa Abi-Dargham
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-23       Impact factor: 6.200

Review 6.  Dopamine receptor homooligomers and heterooligomers in schizophrenia.

Authors:  Melissa L Perreault; Brian F O'Dowd; Susan R George
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

7.  Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine.

Authors:  Gemma Navarro; Estefanía Moreno; Marisol Aymerich; Daniel Marcellino; Peter J McCormick; Josefa Mallol; Antoni Cortés; Vicent Casadó; Enric I Canela; Jordi Ortiz; Kjell Fuxe; Carmen Lluís; Sergi Ferré; Rafael Franco
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

8.  Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Authors:  Jessica A Knight; Carol Smith; Nicole Toohey; Michael T Klein; Milt Teitler
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

9.  Deletion of the NMDA-NR1 receptor subunit gene in the mouse nucleus accumbens attenuates apomorphine-induced dopamine D1 receptor trafficking and acoustic startle behavior.

Authors:  Michael J Glass; Danielle C Robinson; Elizabeth Waters; Virginia M Pickel
Journal:  Synapse       Date:  2013-03-05       Impact factor: 2.562

10.  Detection of receptor heteromers involving dopamine receptors by the sequential BRET-FRET technology.

Authors:  Gemma Navarro; Peter J McCormick; Josefa Mallol; Carme Lluís; Rafael Franco; Antoni Cortés; Vicent Casadó; Enric I Canela; Sergi Ferré
Journal:  Methods Mol Biol       Date:  2013
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.